Dendreon Corp fka DNDNQ

[walldiver]

The Taxotere pivotal Phase III that got its approval had a median survival of 18.9 months in the intent to treat, once per three weeks, Taxotere arm and 16.5 months in the control arm. The once per week Taxotere arm had ~17.0 months MS and was not stat sig. There were ~300 patients in each of the three arms.

However, the TAX327 trial enrollment was split 50-50 between asymptomatic patients and symptomatic patients (bone pain). At the ASCO Prostate Symposium in Feb 07, Sanofi released the subgroup results for the stat sig arm. There were ~150 asymptomatic pts in this arm vs ~150 asymptomatics in the control arm. The MS breakdown for these pts was 23.0 months Tax vs 19.8 months control.

Any CEGE investor not aware of this fact has invested in the stock without knowing the single most important piece of information in CEGE's history as a company.